Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
NVSNegative Net Change RHHBYPositive Net Change MORNegative Net Change ARVNPositive Net Change
biotechs earnings medical pharmaceuticals
4 Stocks to Watch on Their Recent Dividend Hikes
by Ritujay Ghosh
Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.
QCOMPositive Net Change JNJNegative Net Change IBKRNegative Net Change KBHPositive Net Change
finance home-builder medical semiconductor
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
VRTXNegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
New Strong Buy Stocks for April 23rd
by Zacks Equity Research
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
ALPositive Net Change CQPPositive Net Change QUADNegative Net Change FSMNegative Net Change ERASPositive Net Change
construction medical
3 Healthcare Mutual Funds to Grab as the Sector Continues to Rebound
by Zacks Equity Research
JNGLX, VGHCX and FPHAX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.
VGHCXNegative Net Change FPHAXPositive Net Change JNGLXNegative Net Change
medical mutual-funds
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
STEPositive Net Change PODDPositive Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
GILDPositive Net Change ONCYPositive Net Change FATENegative Net Change OMGANegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
HCANegative Net Change PODDPositive Net Change LNTHPositive Net Change EHCNegative Net Change
earnings medical
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
SRPTPositive Net Change ABBVNegative Net Change CTMXNegative Net Change LABPNegative Net Change
biotechs medical pharmaceuticals
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
PODDPositive Net Change EXASPositive Net Change LNTHPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
ADMAPositive Net Change FGENPositive Net Change IMVTNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing
by Zacks Equity Research
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
DVAPositive Net Change CAHNegative Net Change NEOGPositive Net Change PFGCNegative Net Change
medical medical-devices
Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
CAHNegative Net Change EWNegative Net Change WSTNegative Net Change SIBNPositive Net Change
medical medical-devices
Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom
by Zacks Equity Research
Vertiv, Align Technology and DexCom are part of the Zacks Investment Ideas article.
ALGNNegative Net Change DXCMNegative Net Change VRTPositive Net Change
computers medical medical-devices
Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.
HSICPositive Net Change SRPTPositive Net Change PODDPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
Take the Zacks Approach to Beat the Market: Virtu, Coinbase, General Mills in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
PWRPositive Net Change GISNegative Net Change TSCOPositive Net Change HRLPositive Net Change FRPTPositive Net Change CORPositive Net Change CRTONegative Net Change VIRTNegative Net Change MAXPositive Net Change COINPositive Net Change WGSNegative Net Change
consumer-staples finance medical
Top 5 U.S. Giants at Lucrative Valuations Amid April Turmoil
by Nalak Das
We have narrowed our search to five U.S. bigwigs (market capital > $70 billion) with attractive valuations. These are: NVDA, MU, BDX, ANET, EQIX.
EQIXNegative Net Change BDXPositive Net Change MUPositive Net Change NVDAPositive Net Change ANETNegative Net Change
communications medical reit semiconductor
New Strong Sell Stocks for April 22nd
by Zacks Equity Research
AMN, PRG and RKDA have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2024.
AMNPositive Net Change RKDAPositive Net Change PRGNegative Net Change
medical
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
UHSPositive Net Change EWNegative Net Change HCANegative Net Change PODDPositive Net Change
earnings medical
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
VRTXNegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Reasons Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
ECLPositive Net Change DVAPositive Net Change MASIPositive Net Change CORPositive Net Change
medical medical-devices
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
by Zacks Equity Research
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
EWNegative Net Change HOLXPositive Net Change SWAVPositive Net Change HITINo Net Change
earnings medical medical-devices
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
SRPTPositive Net Change VKTXPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
by Zacks Equity Research
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
ECLPositive Net Change DVAPositive Net Change CORPositive Net Change CVRXPositive Net Change
medical medical-devices
What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?
by Zacks Equity Research
Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.
PODDPositive Net Change ZBHNegative Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical